Inactive Instrument

Oncomed Pharmaceuticals Inc

Equities

US68234X1028

Biotechnology & Medical Research

5,310,335 shares of OncoMed Pharmaceuticals, Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 8-JAN-2015.

January 07, 2015

5,310,335 shares of OncoMed Pharmaceuticals, Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 8-JAN-2015. These shares will be under lockup for 540 days starting from 17-JUL-2013 to 8-JAN-2015.

Latest news about Oncomed Pharmaceuticals Inc

Celgene Corporation Announces Update on Etigilimab Partnership	19-06-13	CI
OncoMed Pharmaceuticals, Inc. Announces Executive Resignations in Connection with the Merger Agreement	19-04-23	CI
OncoMed Pharmaceuticals, Inc.(NasdaqGM:OMED) dropped from NASDAQ Composite Index	19-04-23	CI
Mereo BioPharma Group plc completed the acquisition of OncoMed Pharmaceuticals, Inc. from Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., MSI BVF SPV, LLC and Biotechnology Value Trading Fund OS LP managed by BVF Partners LP and others.	19-04-22	CI
OncoMed Pharmaceuticals, Inc.(NasdaqGS:OMED) dropped from S&P TMI Index	19-04-18	CI
OncoMed Pharmaceuticals, Inc. Declares Special Dividend of Contingent Value Rights, Payable on April 5, 2019	19-03-15	CI
OncoMed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2018	19-03-07	CI
Oncomed Pharmaceuticals, Inc. Announces Executive Changes	18-12-06	CI
Transcript : Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc. - M&A Call	18-12-05
Mereo BioPharma Group plc agreed to acquire OncoMed Pharmaceuticals, Inc. for $57.4 million.	18-12-04	CI
OncoMed Announces Early Clinical Data for anti-TIGIT Antibody	18-11-09	CI
Oncomed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Earnings Guidance for the Year 2018	18-11-01	CI
Celgene Notifies OncoMed Pharmaceuticals, Inc. of Its Decision Not to Exercise Option to License Rosmantuzumab and Subsequently Terminated the Companies’ Collaboration Agreement with Respect to Rosmantuzumab, Effective February 12, 2019	18-10-17	CI
OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting	18-10-09	CI
OncoMed Pharmaceuticals, Inc. Announces Resignation of Denise Scots-Knight as Member of the Board	18-10-01	CI
OncoMed Pharmaceuticals, Inc. Announces Publication of Phase 1a Data of Navicixizumab	18-09-24	CI
OncoMed Pharmaceuticals, Inc. Provides Update on Navicixizumab Partnership	18-09-20	CI
Oncomed Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-02	CI
Oncomed Pharmaceuticals Inc. Doses First Patient in Phase 1b Portion of Anti-TIGIT Clinical Trial	18-06-12	CI
OncoMed Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018; Provides Earnings Guidance for the Year 2018	18-05-08	CI
OncoMed Pharmaceuticals Inc. Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting	18-04-18	CI
OncoMed Pharmaceuticals Names John Lewicki as CEO, President, and Member of the Board of Directors	18-03-19	CI
OncoMed Pharmaceuticals, Inc. Appoints Yvonne Li as Principal Accounting Officer and Principal Financial Officer	18-03-19	CI
Transcript : OncoMed Pharmaceuticals, Inc., Q4 2017 Earnings Call, Mar 08, 2018	18-03-08
Oncomed Pharmaceuticals, Inc. Reports Unaudited Earning Results for the Quarter and Year Ended December 31, 2017	18-03-08	CI

Chart Oncomed Pharmaceuticals Inc

Duration

Period

More charts

Company Profile

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research